Jefferies on Axsome Therapeutics (AXSM): balipodect development rights acquisition 'adds depth to CNS pipeline'
Jefferies analyst Andrew Tsai reiterated a Buy rating and $245.00 price target on Axsome Therapeutics (NASDAQ: AXSM)The analyst commented, "For ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)